Stem cells 1996, 14:47–55.PubMedCrossRef 30. Feurino LW, Fisher WE, Bharadwaj U, et al.: Current update of cytokines

in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. Cancer Invest 2006, 24:696–703.PubMedCrossRef 31. Roy S, Kenny E, Kennedy S, et al.: MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res 2007, 27:1325–1330.PubMed 32. Jin Jf, Yuan LD, Liu L, et al.: Preparation and characterization of polyclonal antibodies against ARL-1 protein. World J Gastroenterol 2003, 9:1455–1459.PubMed 33. Stahelin RV, Rafter JD, Das S, et al.: The molecular basis of differential subcellular localization of C2 domains of protein kinase C-alpha and group Iva cytosolic phospholipase A2. J Biol Chem 2003, 278:12452–12460.PubMedCrossRef 34. Padanilam BJ: Induction and subcellular localization of protein kinase C isozymes selleck chemical following renal ischemia. Kidney Int 2001, 59:1789–1797.PubMedCrossRef 35. Gatti A, Robinson PJ: Unique phosphorylation of protein kinase C-alpha in PC12 cells induces resistance to translocation and down-regulation. J Biol Chem 1996, 271:31718–31722.PubMedCrossRef 36. Cloud-Heflin BA, McMasters RA, Osbom MT, et al.: Expression, subcellular distribution and response to phorbo esters of Selleckchem XAV-939 protein kinase C (PKC) isozymes in drug-sensitive

and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. Eur J Biochem 1996, 239:796–804.PubMedCrossRef 37. Lamm ML, Long DD, Goodwin SM, et al.: Transforming growth factor-beta1 inhibits filipin membrane association of protein kinase C alpha in a human prostate cancer cell line, PC3. Endocrinology 1997, 138:4657–4664.PubMedCrossRef 38. Chow JY, Dong H, Quach KT, et al.: TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha acitivation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008, 294:G899–905.PubMedCrossRef

39. Galliher AJ, Schiemann WP: Sre phosphorylates Tyr284 in TGF-beta type II receptor and Linsitinib regulates TGF-beta stimulation of p38 MARK during breast cancer cell proliferation and invaion. Cancer Res 2007, 67:3752–3758.PubMedCrossRef 40. Yu L, Hebert MC, Zhang YE: TGF-beta receptor-activated p38 MARK kinase mediates Smad-independent TGF-beta responses. Embo J 2002, 21:3749–3759.PubMedCrossRef 41. Ellenrieder V, Hendler SF, Boeck W, et al.: Transforming growth factor beta 1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001, 61:4222–4228.PubMed 42. Isonishi S, Ohkawa K, Tanaka T, et al.: Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer 2000, 82:34–38.PubMedCrossRef 43.